Hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy
Not yet reviewed
Date of classification
Drugs not recommended for use in the Leicestershire Health Community because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.
All new drugs will be black until they have been through the appropriate approval process - then they will appear as a specific entry.